Ernexa Therapeutics Inc. Restricted Cash, Noncurrent
Ernexa Therapeutics Inc. (ERNA) had Restricted Cash, Noncurrent of $4.09 million as of 2024-06-30, per its 10-Q filed 2024-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashNoncurrent · last filed 2025-03-12
- 2024-06-30: Restricted Cash, Noncurrent $4.09M.
- 2024-03-31: Restricted Cash, Noncurrent $4.09M.
- 2023-12-31: Restricted Cash, Noncurrent $4.09M.
- 2023-09-30: Restricted Cash, Noncurrent $4.09M.
| Period end | Restricted Cash, Noncurrent |
|---|---|
| 2024-06-30 | $4.09M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $4.09M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $4.09M 10-K · filed 2025-03-12 |
| 2023-09-30 | $4.09M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $4.09M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $4.09M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $4.09M 10-K · filed 2024-03-14 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-20 |
| 2020-03-31 | $150.00K 10-Q · filed 2020-05-20 |
| 2019-12-31 | $150.00K 10-K · filed 2021-03-11 |
| 2019-09-30 | $200.00K 10-Q · filed 2020-11-13 |
| 2019-06-30 | $200.00K 10-Q · filed 2020-08-07 |
| 2019-03-31 | $200.00K 10-Q · filed 2020-05-20 |
| 2018-12-31 | $200.00K 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |